Loading stock data…
Vir Biotechnology (VIR)
$10.27+0.24 (+2.39%)
Market OpenUpdated 3:02 PM EDT
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Vir Biotechnology, Inc. in the Healthcare sector is trading at $10.27 with a market capitalization of $1.4B. Wall Street consensus targets $21.56 (9 analysts), implying a +109.9% move over the next 12 months. The stock is currently near its 52-week high of $11.66, remaining 35.1% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +109.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | -$41,000↓ | $63.76M↑ | -$65,000↓ | $1.03M↓ | $1.79M |
| Gross Profit | — | $63.73M↑ | -$54,000↓ | $1.02M↓ | $1.79M |
| Operating Income | -$132.29M↓ | -$47.92M↑ | -$173.44M↓ | -$118.59M↑ | -$139.56M |
| Net Income | -$125.69M↓ | -$42.92M↑ | -$163.14M↓ | -$110.96M↑ | -$120.97M |
Peer Comparison
JNJUNHPFE
Fundamentals
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.44B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-54.47%
Volume
Today's trading volume
904,733
Recent News
Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?
Is VIR a good stock to buy? We came across a bullish thesis on Vir Biotechnology, Inc. on Valueinvestorsclub.com by Bohr. In this article, we will summarize the bulls’ thesis on VIR. Vir Biotechnology, Inc.’s share was trading at $9.19 as of May 25th. VIR’s trailing P/E was 5.92 according to Yahoo Finance. Vir Biotechnology, Inc., a […]
How SOLSTICE Phase 2 HDV Data at Vir Biotechnology (VIR) Has Changed Its Investment Story
Vir Biotechnology recently announced it will present data from its Phase 2 SOLSTICE trial of the tobevibart-elebsiran combination for chronic hepatitis delta at the EASL Congress 2026 in Barcelona, highlighting a potential new approach in an area with few existing treatment options. The trial’s focus on driving hepatitis delta virus RNA to undetectable levels, a marker linked with better clinical outcomes, underscores why this program is drawing heightened attention from both clinicians and...
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally
Vir Biotechnology develops immunology-based therapies targeting infectious diseases through global partnerships and scientific innovation.
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million
Vir Biotechnology develops immunology-based therapies for infectious diseases, backed by collaborations and a diversified research pipeline.
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares
Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust clinical pipeline.